Home › Companies › VIKING THERAPEUTICS INC. › 2024-2025
Compiled from SEC Form N-PX filings and VIKING THERAPEUTICS INC.’s Form 8-K, filed 2025-05-27 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore VIKING THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are VIKING THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-27 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Matthew W. Foehr | 28,050,978 | -- | -- | 16,211,847 | 32,427,944 | Majority: yes |
| Elect Director: Charles A. Rowland, Jr. | 32,982,998 | -- | -- | 11,279,827 | 32,427,944 | Majority: yes |
| Proposal 2: . To ratify the selection of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025: | 75,225,572 | 992,111 | 473,085 | -- | -- | Majority: yes |
| Proposal 3: . To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement: | 29,265,273 | 14,490,719 | 506,834 | -- | 32,427,943 | Majority: yes |
Source: VIKING THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-05-27 — read the filing on EDGAR.
Each item below shows how the 410 asset managers that disclosed a VIKING THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of VIKING THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held 2025-05-20.
Combines 11 wordings of this item as funds reported it.
67% Majority: yes · of votes cast
VIKING THERAPEUTICS INC.’s own tally for this item (“Proposal 3: . To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement:”): 29,265,273 for, 14,490,719 against, per its Form 8-K filed 2025-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 112,288,759 outstanding shares: 26% for, 13% against (39% of the company cast a for/against vote).
The 398 asset managers below cast 72% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,558,068 | 9,266 | 0 | 0 | For |
| Fidelity | 8,920,836 | 738,723 | 0 | 0 | For |
| BlackRock | 3,820,871 | 29,667 | 0 | 0 | For |
| JPMorgan | 3,262,758 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 0 | 1,714,062 | 0 | 0 | Against |
| State Street | 1,476,521 | 11,739 | 0 | 0 | For |
| Charles Schwab | 0 | 1,425,448 | 0 | 0 | Against |
| AllianceBernstein | 1,216,174 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 0 | 1,025,604 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 707,201 | 0 | 0 | Against |
| PNC BANK, NATIONAL ASSOCIATION | 656,037 | 0 | 0 | 0 | For |
| Clearbridge Investments, LLC | 631,764 | 0 | 0 | 0 | For |
| Voya | 513,560 | 47,179 | 0 | 0 | For |
| BRAIDWELL LP | 0 | 443,354 | 0 | 0 | Against |
| Putnam | 0 | 416,954 | 0 | 0 | Against |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | 393,849 | 0 | 0 | Against |
| BAMCO INC /NY/ | 0 | 387,319 | 0 | 0 | Against |
| STIFEL NICOLAUS & CO INC \MO\ | 0 | 376,556 | 0 | 0 | Against |
| PRINCIPAL GLOBAL INVESTORS | 0 | 363,579 | 0 | 0 | Against |
| Delaware/Macquarie | 0 | 330,100 | 0 | 0 | Against |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 0 | 330,100 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 313,359 | 0 | 0 | Against |
| Principal | 53,327 | 251,300 | 0 | 0 | Against |
| AB DISCOVERY GROWTH FUND, INC. | 287,965 | 0 | 0 | 0 | For |
| Northern Trust | 265,044 | 10,536 | 0 | 0 | For |
Showing the 25 largest of 398 asset managers. See all 398 in the interactive database.
Meeting held 2025-05-20.
Combines 5 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
VIKING THERAPEUTICS INC.’s own tally for this item (“Proposal 2: . To ratify the selection of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025:”): 75,225,572 for, 992,111 against, per its Form 8-K filed 2025-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 112,288,759 outstanding shares: 67% for, 0.9% against (68% of the company cast a for/against vote).
The 82 asset managers below cast 99.7% of the shares they voted on this item FOR (22,485,525 for, 66,644 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,303,691 | 0 | 0 | 0 | For |
| Fidelity | 4,069,602 | 0 | 0 | 0 | For |
| JPMorgan | 1,268,035 | 0 | 0 | 0 | For |
| BlackRock | 1,221,928 | 0 | 0 | 0 | For |
| Charles Schwab | 709,625 | 0 | 0 | 0 | For |
| State Street | 408,523 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 330,100 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 313,359 | 0 | 0 | 0 | For |
| Principal | 304,627 | 0 | 0 | 0 | For |
| AllianceBernstein | 295,481 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 287,965 | 0 | 0 | 0 | For |
| BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND) | 258,600 | 0 | 0 | 0 | For |
| Voya | 256,780 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 255,407 | 0 | 0 | 0 | For |
| Legg Mason | 240,200 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 236,880 | 0 | 0 | 0 | For |
| Putnam | 198,320 | 0 | 0 | 0 | For |
| TIAA | 159,860 | 0 | 0 | 0 | For |
| Equitable | 122,653 | 0 | 0 | 0 | For |
| Harbor Funds II | 115,189 | 0 | 0 | 0 | For |
| Northwestern Mutual | 100,328 | 0 | 0 | 0 | For |
| Russell Investments | 94,493 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 80,594 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 80,058 | 0 | 0 | 0 | For |
| BARON SELECT FUNDS | 74,811 | 0 | 0 | 0 | For |
Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.
Meeting held 2025-05-20.
Combines 7 wordings of this item as funds reported it.
75% Majority: yes · of votes cast
VIKING THERAPEUTICS INC.’s own tally for this item (“Elect Director: Charles A. Rowland, Jr.”): 32,982,998 for, 11,279,827 withheld, per its Form 8-K filed 2025-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 112,288,759 outstanding shares: 29% for, 10% withheld (39% of the company cast a for/withheld vote).
The 78 asset managers below cast 100% of the shares they voted on this item FOR (16,847,297 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,303,687 | 0 | 4 | 0 | For |
| Fidelity | 746,449 | 0 | 3,323,153 | 0 | Abstain |
| JPMorgan | 1,268,035 | 0 | 0 | 0 | For |
| BlackRock | 1,221,928 | 0 | 0 | 0 | For |
| Charles Schwab | 709,625 | 0 | 0 | 0 | For |
| State Street | 408,037 | 0 | 486 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 330,100 | 0 | Abstain |
| Columbia Threadneedle | 313,359 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 304,627 | 0 | Abstain |
| AllianceBernstein | 0 | 0 | 295,481 | 0 | Abstain |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 287,965 | 0 | Abstain |
| BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND) | 258,600 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 256,780 | 0 | Abstain |
| MUTUAL FUND SERIES TRUST | 255,407 | 0 | 0 | 0 | For |
| Legg Mason | 240,200 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 236,880 | 0 | 0 | 0 | For |
| Putnam | 198,320 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 159,860 | 0 | Abstain |
| Equitable | 7,215 | 0 | 115,438 | 0 | Abstain |
| Harbor Funds II | 115,189 | 0 | 0 | 0 | For |
| Northwestern Mutual | 100,328 | 0 | 0 | 0 | For |
| Russell Investments | 94,493 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 80,594 | 0 | Abstain |
| MASTER INVESTMENT PORTFOLIO | 80,058 | 0 | 0 | 0 | For |
| BARON SELECT FUNDS | 74,811 | 0 | 0 | 0 | For |
Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.
Meeting held 2025-05-20.
Combines 7 wordings of this item as funds reported it.
63% Majority: yes · of votes cast
VIKING THERAPEUTICS INC.’s own tally for this item (“Elect Director: Matthew W. Foehr”): 28,050,978 for, 16,211,847 withheld, per its Form 8-K filed 2025-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 112,288,759 outstanding shares: 25% for, 14% withheld (39% of the company cast a for/withheld vote).
The 78 asset managers below cast 100% of the shares they voted on this item FOR (15,095,041 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,303,686 | 0 | 4 | 0 | For |
| Fidelity | 700,350 | 0 | 3,369,252 | 0 | Abstain |
| JPMorgan | 1,268,035 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 1,221,928 | 0 | Abstain |
| Charles Schwab | 709,625 | 0 | 0 | 0 | For |
| State Street | 1,008 | 0 | 407,515 | 0 | Abstain |
| Delaware/Macquarie | 0 | 0 | 330,100 | 0 | Abstain |
| Columbia Threadneedle | 313,359 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 304,627 | 0 | Abstain |
| AllianceBernstein | 0 | 0 | 295,481 | 0 | Abstain |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 287,965 | 0 | Abstain |
| BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND) | 258,600 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 256,780 | 0 | Abstain |
| MUTUAL FUND SERIES TRUST | 255,407 | 0 | 0 | 0 | For |
| Legg Mason | 240,200 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 236,880 | 0 | 0 | 0 | For |
| Putnam | 198,320 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 159,860 | 0 | Abstain |
| Equitable | 0 | 0 | 122,653 | 0 | Abstain |
| Harbor Funds II | 115,189 | 0 | 0 | 0 | For |
| Northwestern Mutual | 100,328 | 0 | 0 | 0 | For |
| Russell Investments | 94,493 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 80,594 | 0 | Abstain |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 80,058 | 0 | Abstain |
| BARON SELECT FUNDS | 74,811 | 0 | 0 | 0 | For |
Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.
Meeting held 2024-05-21 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).
93% Majority: yes · of votes cast
VIKING THERAPEUTICS INC.’s own tally for this item (“Proposal 3: . To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement:”): 63,234,707 for, 4,510,461 against, per its Form 8-K filed 2024-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 112,288,759 outstanding shares: 56% for, 4% against (60% of the company cast a for/against vote).
The 3 asset managers below cast 83% of the shares they voted on this item FOR (2,246 for, 450 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Americana Partners, LLC | 2,216 | 0 | 0 | 0 | For |
| COLDSTREAM CAPITAL MANAGEMENT INC | 0 | 450 | 0 | 0 | Against |
| VAUGHAN DAVID INVESTMENTS LLC/IL | 30 | 0 | 0 | 0 | For |
Meeting held 2025-05-20.
67% Majority: yes · of votes cast
VIKING THERAPEUTICS INC.’s own tally for this item (“Proposal 3: . To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement:”): 29,265,273 for, 14,490,719 against, per its Form 8-K filed 2025-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 112,288,759 outstanding shares: 26% for, 13% against (39% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (42 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Blue Sky Capital Consultants Group, Inc. | 25 | 0 | 0 | 0 | For |
| Capital Group | 17 | 0 | 0 | 0 | For |
Meeting held 2025-05-20.
67% Majority: yes · of votes cast
VIKING THERAPEUTICS INC.’s own tally for this item (“Proposal 3: . To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement:”): 29,265,273 for, 14,490,719 against, per its Form 8-K filed 2025-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 112,288,759 outstanding shares: 26% for, 13% against (39% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (183 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Empower | 183 | 0 | 0 | 0 | For |
| Ikarian Capital, LLC | 0 | 0 | 0 | 0 | -- |
Showing the 7 reported items with the widest manager coverage, of 8 in total. View every item.
Ranked by the number of VIKING THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 112,288,759 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.41% |
| 2 | Fidelity | 8.60% |
| 3 | BlackRock | 3.43% |
| 4 | JPMorgan | 2.91% |
| 5 | PICTET ASSET MANAGEMENT SA | 1.53% |
| 6 | State Street | 1.33% |
| 7 | Charles Schwab | 1.27% |
| 8 | AllianceBernstein | 1.08% |
| 9 | AMERIPRISE FINANCIAL INC | 0.91% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 0.63% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR LLC | 13.36% | DEF14A |
| FMR (Fidelity) | 10.02% | 13F |
| Vanguard Group | 9.05% | 13F |
| BlackRock | 5.32% | 13F |
| State Street | 3.61% | 13F |
| Citadel Advisors | 3.40% | 13F |
| Brian Lian, Ph.D. | 2.91% | DEF14A |
| JPMorgan Chase | 2.78% | 13F |
| Morgan Stanley | 2.78% | 13F |
| Northern Trust | 0.48% | 13F |
Percentages above are of 112,288,759 shares outstanding, as reported by VIKING THERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from VIKING THERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At VIKING THERAPEUTICS INC.'s shareholder meeting held 2025-05-20, in the 2024-2025 proxy season, 410 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,531 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 67% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: VIKING THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-05-27.
VIKING THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.